Boston Business Journal

GSK acquires Massachusetts cancer biotech in $1.1B deal

GSK is buying a Plymouth-based cancer drug developer.

As the first morning of the J.P. Morgan Healthcare Conference dawns, GSK plc is entering the deal-making conversation with a planned acquisition of IDRx, a Plymouth-based biotech working on precision treatments for gastrointestinal stromal tumours.

The British pharma giant said the acquisition includes IDRx’s lead drug candidate, IDRX-42, in development for this rare type of cancer. IDRX-42 is in an ongoing Phase 1/1b trial in patients with advanced GIST.

WATCH ANYTIME FOR FREE

icon

Stream NBC10 Boston news for free, 24/7, wherever you are.

More on this story from Boston Business Journal

Copyright Boston Business Journal
Contact Us